We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+15.01%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$115M
AUM Growth
+$35.6M
Cap. Flow
+$33.1M
Cap. Flow %
28.7%
Top 10 Hldgs %
16.88%
Holding
267
New
23
Increased
109
Reduced
60
Closed
21

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$1.39M
2
INDA icon
iShares MSCI India ETF
INDA
+$872K
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$767K
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$708K
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$648K

Top Sells

Rank Stock Value
1
UPW icon
ProShares Ultra Utilities
UPW
+$1.11M
2
VDE icon
Vanguard Energy ETF
VDE
+$755K
3
RXDX
Ignyta, Inc.
RXDX
+$612K
4
FTEC icon
Fidelity MSCI Information Technology Index ETF
FTEC
+$430K
5
JUNO
Juno Therapeutics, Inc.
JUNO
+$359K

Sector Composition

Rank Sector Weight
1 Healthcare 78.8%
2 Financials 0.81%
3 Technology 0.51%
4 Consumer Discretionary 0.44%
5 Communication Services 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTLA
101
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$627K 0.54%
19,203
-1,115
-5% -$48.9K
CRBP icon
102
Corbus Pharmaceuticals
CRBP
$170M
$625K 0.54%
3,416
+1,835
+116% +$412K
PBYI icon
103
Puma Biotechnology
PBYI
$406M
$621K 0.54%
9,129
-532
-6% -$39.8K
FPRX
104
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$621K 0.54%
36,128
+18,757
+108% +$366K
RETA
105
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$617K 0.54%
30,088
+16,171
+116% +$416K
CLDX icon
106
Celldex Therapeutics
CLDX
$2.77B
$597K 0.52%
17,095
+9,164
+116% +$355K
MCRB icon
107
Seres Therapeutics
MCRB
$48M
$563K 0.49%
3,836
+2,071
+117% +$397K
CALA
108
DELISTED
Calithera Biosciences, Inc
CALA
$559K 0.49%
4,436
+2,353
+113% +$367K
PRTK
109
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$556K 0.48%
42,733
+23,153
+118% +$345K
INSM icon
110
Insmed
INSM
$23.2B
$550K 0.48%
24,409
+12,915
+112% +$340K
OMER icon
111
Omeros
OMER
$709M
$528K 0.46%
47,276
-2,789
-6% -$39.2K
AKBA icon
112
Akebia Therapeutics
AKBA
$327M
$481K 0.42%
50,462
+27,003
+115% +$378K
TTPH
113
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$402K 0.35%
6,546
+3,564
+120% +$313K
MLNT
114
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$363K 0.32%
9,806
+5,395
+122% +$355K
MRNS
115
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$307K 0.27%
20,097
+10,646
+113% +$253K
BABA icon
116
Alibaba
BABA
$269B
$212K 0.18%
1,153
+389
+51% +$73.2K
SIOX
117
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$184K 0.16%
17,296
+9,010
+109% +$145K
ITUB icon
118
Itaú Unibanco
ITUB
$91.3B
$171K 0.15%
22,553
+503
+2% +$3.77K
HDB icon
119
HDFC Bank
HDB
$119B
$153K 0.13%
6,188
+3,856
+165% +$97.2K
AMX icon
120
America Movil
AMX
$78.1B
$150K 0.13%
7,841
+1,497
+24% +$27.7K
ABEV icon
121
Ambev
ABEV
$47.3B
$113K 0.1%
15,484
+893
+6% +$6.14K
FMX icon
122
Fomento Económico Mexicano
FMX
$43.3B
$104K 0.09%
1,133
+281
+33% +$26.3K
SQM icon
123
Sociedad Química y Minera de Chile
SQM
$19.6B
$103K 0.09%
+2,101
New +$114K
PBR.A icon
124
Petrobras Class A
PBR.A
$107B
$92K 0.08%
7,099
+102
+1% +$1.25K
JD icon
125
JD.com
JD
$40.8B
$64K 0.06%
1,580
+428
+37% +$19.4K
3 4
5
6 7

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q1 2018 Portfolio in Review

As of Q1 2018, Virtus ETF Advisers held 267 positions worth $115M, up 45% from $79.7M the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Virtus ETF Advisers deployed $33.1M of net new capital in Q1 2018, opening 23 new positions and adding to 109 existing holdings. Its largest new stake was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 71% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Vanguard Energy ETF, an estimated $755K trimmed.

  • Virtus ETF Advisers's largest Q1 2018 buy was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.
  • Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q1 2018, an estimated $1.39M increase.
  • Virtus ETF Advisers's biggest Q1 2018 reduction was Vanguard Energy ETF, cutting an estimated $755K.
  • Virtus ETF Advisers fully exited ProShares Ultra Utilities in Q1 2018, selling an estimated $1.11M.
  • Virtus ETF Advisers's ten largest holdings make up 17% of its $115M portfolio in Q1 2018.
  • Virtus ETF Advisers opened 23 new positions and closed 21 in Q1 2018.
  • Virtus ETF Advisers's portfolio value rose 45% quarter-over-quarter to $115M.

Based on Virtus ETF Advisers's 13F filing for Q1 2018, filed 14 May 2018.